KISUNEE Trademark

Trademark Overview


On Tuesday, June 8, 2021, a trademark application was filed for KISUNEE with the United States Patent and Trademark Office. The USPTO has given the KISUNEE trademark a serial number of 90761512. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, January 6, 2025. This trademark is owned by Eli Lilly and Company. The KISUNEE trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of Alzheimer's disease, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease, dementia, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, vascular diseases
kisunee

General Information


Serial Number90761512
Word MarkKISUNEE
Filing DateTuesday, June 8, 2021
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, January 6, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 5, 2022

Trademark Statements


Goods and ServicesPharmaceutical preparations, namely, pharmaceutical preparations for the treatment of Alzheimer's disease, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease, dementia, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, vascular diseases

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateSunday, August 29, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameEli Lilly and Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Party NameEli Lilly and Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Trademark Events


Event DateEvent Description
Friday, June 11, 2021NEW APPLICATION ENTERED
Sunday, August 29, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, January 18, 2022ASSIGNED TO EXAMINER
Tuesday, January 18, 2022NON-FINAL ACTION WRITTEN
Tuesday, January 18, 2022NON-FINAL ACTION E-MAILED
Tuesday, January 18, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, February 28, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, February 28, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, March 1, 2022ASSIGNED TO LIE
Tuesday, March 1, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, March 1, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, March 16, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 5, 2022PUBLISHED FOR OPPOSITION
Tuesday, April 5, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, May 31, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, October 18, 2022SOU TEAS EXTENSION RECEIVED
Tuesday, October 18, 2022SOU EXTENSION 1 FILED
Thursday, October 27, 2022CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, October 27, 2022SOU EXTENSION 1 GRANTED
Friday, October 28, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, April 17, 2023SOU TEAS EXTENSION RECEIVED
Monday, April 17, 2023SOU EXTENSION 2 FILED
Monday, April 17, 2023SOU EXTENSION 2 GRANTED
Wednesday, April 19, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, October 16, 2023SOU TEAS EXTENSION RECEIVED
Monday, October 16, 2023SOU EXTENSION 3 FILED
Monday, October 16, 2023SOU EXTENSION 3 GRANTED
Wednesday, October 18, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, April 16, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, April 16, 2024SOU EXTENSION 4 FILED
Tuesday, April 16, 2024SOU EXTENSION 4 GRANTED
Wednesday, April 17, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, January 6, 2025ABANDONMENT - NO USE STATEMENT FILED
Monday, January 6, 2025ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED